Core Viewpoint - 京玖康疗 reported a significant improvement in its financial performance for the first half of 2025, achieving a revenue of HKD 35.77 million, which represents a year-on-year increase of 16.5% and a turnaround from a loss to a profit for shareholders [1] Financial Performance - Revenue reached HKD 35.77 million, marking a 16.5% increase compared to the previous year [1] - Shareholders' profit amounted to HKD 3.353 million, a significant recovery from a loss of HKD 6.093 million in the same period last year [1] - Basic earnings per share were reported at HKD 0.01 [1] Growth Drivers - The revenue growth is attributed to the company's ongoing efforts to expand its product sources and broaden its product portfolio [1]